Cortex CX717 ADHD clinical hold
This article was originally published in Pharmaceutical Approvals Monthly
A clinical hold placed on Cortex' investigational attention deficit hyperactivity disorder agent CX717 is based on preclinical animal data, the firm says April 13 after receiving a letter from FDA explaining the decision. "Based on the terms in the letter, the company has begun the process to arrange for discussions with the appropriate experts within the agency to translate the request into specific acute preclinical studies related to the issues and recommendations provided by the agency," the Irvine, Calif. firm states. Cortex' development focus is its proprietary Ampakine compounds, one of which is CX717. The firm has multiple patents for the agents, which bind to the AMPA receptors to increase signal strength in connections between brain cells...
You may also be interested in...
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.